The recurrence rate of extramedullary plasmacytoma is high but varies from person to person.
Extramedullary plasmacytoma belongs to a specific type of multiple myeloma that includes classifications such as bone-associated plasmacytoma, extramedullary lesions, plasma cell leukemia, and isolated plasmacytoma. Extramedullary plasmacytoma accounts for 6-8% of first diagnosed multiple myeloma and 10%-30% of relapsed and refractory cases.
Therefore, the recurrence rate of extramedullary plasmacytoma is high. However, for different individual patients, the recurrence rate varies from person to person. Some patients can achieve long-term remission after aggressive treatment with surgery, combination chemotherapy, targeted therapy, and radiation therapy. Drugs include cyclophosphamide, bortezomib, and daltuzumab.
If patients with extramedullary plasmacytoma are accompanied by multiple chromosomal mutations or poor fusion gene expression, the treatment efficacy is often poor, and the recurrence rate of this type of extramedullary plasmacytoma will be significantly higher, and the disease even progresses during the treatment period.
It is recommended that patients should consult the Department of Hematology in a timely manner, and have individualized treatment plans formulated by specialists according to their specific conditions, so as to prolong the survival period of the patients as much as possible and improve their quality of life.